ArticleJournal of gastrointestinal oncology2025
D-dimer predicts the response of patients with gastric cancer to first-line immunotherapy combined with chemotherapy.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy in cancer.Annals of medicine · 2026Pooled it
- From bench to knowledge graph: mapping the global evolution of PD-1/PD-L1 immunotherapy in gastric cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have emerged as a new choice for advanced and metastatic gastric cancer (GC) patients. Due to the lack of unified and effective predictive biomarkers, there is an urgent need to find accurate biomarkers. The aim of our study was to explore the prognostic value of the pretreatment D-dimer levels on the effect of immunotherapy combined with chemotherapy in advanced and metastatic GC patients. Methods: We retrospectively reviewed 40 advanced and metastatic GC patients receiving programmed death 1/programmed death ligand-1 (PD-1/PD-L1) inhibitors. The optimal D-dimer cut-off value was calculated based on the Youden index for overall survival (OS). The efficacy and prognostic outcomes of ICIs combined with chemotherapy in patients with advanced or metastatic GC were assessed across subgroups stratified by pretreatment D-dimer levels. Univariate and multivariate regression analyses were performed to evaluate the potential prognostic factors for progression-free survival (PFS) and OS. Results: The optimal cut-off value of D-dimer was 0.965 µg/mL, with a sensitivity and specificity of 0.857 and 0.789, respectively, based on the receiver operating characteristic (ROC) curve and Youden index. The low D-dimer group exhibited higher disease control rate (DCR) compared to the high D-dimer group (72.2% Conclusions: Pretreatment D-dimer level may be an independent predictive biomarker for efficacy and prognosis in advanced and metastatic GC patients receiving first-line immunotherapy combined with chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.